Ceregene is a biotechnology company focused on developing neurotrophic growth factor treatments for major neurodegenerative disorders using a proprietary gene delivery technology. It offers gene therapy products for Alzheimer’s disease and Parkinson’s disease. The company also has research programs investigating therapies for other neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), ocular diseases such as retinitis pigmentosa (RP), age-related macular degeneration (AMD), and glaucoma, and Huntington’s disease.
Parent CompanySangamo Therapeutics
Ceregene was founded in 2001

Viewing summary data as a guest

Sign up for free to see all data
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Ceregene

Stephen Sherwin

Stephen Sherwin

Co-Founder & Chairman
Arpesh Mehta

Arpesh Mehta

Senior Research Associate
Show more

Ceregene Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$39.5 m


Ceregene is a subsidiary of Sangamo Therapeutics

Ceregene Online and Social Media Presence

Embed Graph

Ceregene Frequently Asked Questions

  • When was Ceregene founded?

    Ceregene was founded in 2001.

  • Who are Ceregene key executives?

    Ceregene's key executives are Stephen Sherwin and Arpesh Mehta.

  • How many employees does Ceregene have?

    Ceregene has 30 employees.

  • Who are Ceregene competitors?

    Competitors of Ceregene include Neurim Pharmaceuticals, Stalicla and Suven Life Sciences.